Noetik CEO Ron Alfa (L) and CSO Jacob Rinaldi
August 28, 2024 07:00 AM EDTUpdated August 30, 02:51 AM
Financing
Startups
AI

Ex­clu­sive: Noetik rais­es $40M Se­ries A to ad­vance AI am­bi­tions in can­cer — with an un­like­ly lead in­vestor

Andrew Dunn

Senior Biopharma Correspondent

Af­ter serv­ing as Pfiz­er’s top lawyer and now chair­ing Al­ny­lam’s board, Amy Schul­man’s lat­est biotech bet could be seen as some­what of a sur­prise. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

Af­ter a huge IPO and ac­qui­si­tion, Zymer­gen caps off bank­rupt­cy with $30M SEC penal­ty

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

A service from the Financial Times